VNDA
Vanda Pharmaceuticals Inc.Company Information
- Company Name
- Vanda Pharmaceuticals Inc.
- CIK
- CIK0001347178
- Category
- Accelerated filer
- Ticker: Exchange
- VNDA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VNDA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-07
- Last sale
- 2026-03-02
- Shares purchased (TTM)
- 70,000
- Shares sold (TTM)
- 351,342
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,940,023
- Shares outstanding
- 60,226,570
- Ownership
- 77.94%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 3.32%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 56 | 54 | 85 | 70 | 81 | 112 | 102 | 100 | 103 | 125 | 136 | 183 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | 114 | 148 | 179 | 224 | 245 | 229 | 272 | 276 | 285 | 269 | 252 | 307 | ||||||
| Accounts Receivable Net Current | 60 | 57 | 55 | 51 | 45 | 45 | 47 | 43 | 42 | 37 | 34 | 29 | ||||||
| Inventory Net | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 33 | 32 | 27 | 21 | 22 | 20 | 15 | 12 | 8 | 7 | 9 | 16 | ||||||
| Assets Current | 264 | 293 | 347 | 367 | 395 | 408 | 439 | 432 | 439 | 439 | 433 | 537 | ||||||
| Property Plant And Equipment Net | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 15 | 5 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | ||||||
| Finance Lease Right Of Use Asset | 7 | 7 | 7 | 5 | 5 | 5 | 5 | - | - | - | 0 | - | ||||||
| Finite Lived Intangible Assets Net | 113 | 115 | 117 | 109 | 111 | 112 | 114 | 116 | 118 | 119 | 121 | 17 | ||||||
| Deferred Income Tax Assets Net | - | - | 0 | 103 | 97 | 89 | 81 | 79 | 77 | 75 | 75 | 68 | ||||||
| Assets | 412 | 434 | 489 | 601 | 625 | 632 | 656 | 645 | 651 | 653 | 648 | 642 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 70 | 61 | 68 | 48 | 57 | 45 | 39 | 39 | 40 | 38 | 38 | 33 | ||||||
| Liabilities Current | 164 | 136 | 145 | 118 | 121 | 104 | 100 | 89 | 94 | 93 | 88 | 85 | ||||||
| Operating Lease Liability Noncurrent | 15 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | ||||||
| Finance Lease Liability Noncurrent | 3 | 4 | 4 | 3 | 3 | 3 | 3 | - | - | - | 0 | - | ||||||
| Other Liabilities Noncurrent | 10 | 10 | 10 | 11 | 10 | 9 | 10 | 9 | 9 | 9 | 9 | 6 | ||||||
| Liabilities | 192 | 153 | 162 | 135 | 138 | 121 | 118 | 104 | 109 | 109 | 104 | 99 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 726 | 724 | 721 | 719 | 717 | 715 | 713 | 710 | 707 | 704 | 700 | 697 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | -0 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -506 | -443 | -395 | -254 | -231 | -204 | -174 | -169 | -164 | -160 | -155 | -153 | ||||||
| Stockholders Equity | 220 | 281 | 327 | 466 | 486 | 511 | 539 | 541 | 543 | 544 | 545 | 543 | ||||||
| Liabilities And Stockholders Equity | 412 | 434 | 489 | 601 | 625 | 632 | 656 | 645 | 651 | 653 | 648 | 642 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 60 | 60 | 59 | 59 | 59 | 59 | 58 | 58 | 58 | 58 | 58 | 58 | ||||||
| Shares Outstanding | 60 | 60 | 59 | 59 | 59 | 59 | 58 | 58 | 58 | 58 | 58 | 58 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVanda Pharmaceuticals Inc. (VNDA) — SEC Financial Statements & Analysis
Vanda Pharmaceuticals Inc. (VNDA) is a pharmaceutical preparations company, incorporated in DE. Vanda Pharmaceuticals Inc. trades on Nasdaq as: VNDA. Vanda Pharmaceuticals Inc. (VNDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Vanda Pharmaceuticals Inc. carries a market cap of $368.59M, a P/E ratio of -1.34x, a P/B ratio of 1.67x, a P/S ratio of 1.71x, an enterprise value of $315.41M, and an EV/EBITDA multiple of -1.71x. On profitability, it posts a gross margin of 93.74%, an operating margin of -86.07%, a net margin of -127.41%, a Return on Equity (ROE) of -77.81%, a Return on Assets (ROA) of -53.00%, and a Return on Invested Capital (ROIC) of -63.66%. Per share, it reports EPS of $-4.56, diluted EPS of $-4.56, free cash flow per share of $-2.37, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 6.02% year-over-year, net income growth of 310.61% year-over-year, and EPS growth of 302.21% year-over-year. On the balance sheet, it maintains a current ratio of 1.61x, a quick ratio of 1.40x, working capital of $100.46M, a debt-to-equity ratio of 0.87x, a debt ratio of 0.47, free cash flow of $-143.00M (TTM), and net debt of $-53.18M. Figures sourced from SEC EDGAR.
- Market Cap
- $368.59M
- P/E TTM
- -1.34x
- EPS TTM
- $-4.56
- P/B TTM
- 1.67x
- ROE TTM
- -77.81%
- ROA TTM
- -53.00%
- Debt To Equity
- 0.87x
- Free Cash Flow TTM
- $-143.00M
- Net Revenue TTM Growth 1Y
- 6.02%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vanda Pharmaceuticals Inc. in?
Vanda Pharmaceuticals Inc. (VNDA) operates in the Pharmaceutical Preparations industry.
What exchange does VNDA trade on?
Vanda Pharmaceuticals Inc. (VNDA) trades on the Nasdaq.
Where is Vanda Pharmaceuticals Inc. incorporated?
Vanda Pharmaceuticals Inc. is incorporated in DE.
When was Vanda Pharmaceuticals Inc. (VNDA)'s most recent SEC filing?
Vanda Pharmaceuticals Inc. (VNDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is VNDA's market cap?
Vanda Pharmaceuticals Inc. (VNDA) has a market capitalization of $368.59M as of 2026-06-30.
What is VNDA's EPS (earnings per share)?
Vanda Pharmaceuticals Inc. (VNDA)'s trailing twelve month EPS is $-4.56 as of 2026-06-30.
What is VNDA's ROE (return on equity)?
Vanda Pharmaceuticals Inc. (VNDA)'s trailing twelve month Return on Equity (ROE) is -77.81% as of 2026-06-30.
What is VNDA's ROA (return on assets)?
Vanda Pharmaceuticals Inc. (VNDA)'s trailing twelve month Return on Assets (ROA) is -53.00% as of 2026-06-30.
What is VNDA's ROIC (return on invested capital)?
Vanda Pharmaceuticals Inc. (VNDA)'s trailing twelve month Return on Invested Capital (ROIC) is -63.66% as of 2026-06-30.
What is VNDA's EV/EBITDA?
Vanda Pharmaceuticals Inc. (VNDA)'s trailing twelve month EV/EBITDA is -1.71x as of 2026-06-30.